Wellgistics Health Releases Letter to Our Shareholders
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX)/b) shared a strategic update tied to a binding term sheet with Datavault AI to integrate the EinsteinRx AI dispensing platform into PharmacyChain, its blockchain smart-contract system.The letter details planned vertical integration moves, including DelivMeds AI, QOLPOM patents, Tollo Health, Forzet, and a planned share restructuring with a new CUSIP.
Positive
- Binding term sheet with Datavault AI to integrate EinsteinRx into PharmacyChain
- Formation of DelivMeds AI plus expanded Datavault license for tokenized healthcare data
- Planned acquisition of QOLPOM patent portfolio for biometric verification and drone delivery IP
- Planned controlling interest in Tollo Health and Forzet platform to reach patients directly
- Health Lives Here GLP-1 program expected to generate adherence, outcome, and biometric data
- Planned share restructuring and new CUSIP aligned with next growth phase
Negative
- None.
News Market Reaction – WGRX
In the May 21 session, WGRX declined 17.05%, reflecting a significant negative market reaction. Argus tracked a trough of -17.6% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Strategic transactions | Positive | -25.6% | Binding term sheet for DelivMeds AI and multi-asset healthcare data deal. |
| May 19 | Earnings update | Positive | -25.6% | Q1 2026 revenue growth and narrowed operating loss with business update. |
| May 15 | Earnings date notice | Neutral | +108.4% | Announcement of timing for release of Q1 2026 financial results. |
| May 14 | Acquisition LOI | Positive | -3.1% | Non-binding LOI to acquire WellCare Today and its RPM/RTM/CCM platform. |
| May 13 | Partnership pilot | Positive | +23.1% | MSO collaboration with Kare PharmTech for CCM and RPM services. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several sharp selloffs on ostensibly positive strategic and earnings news, with occasional strong upside on anticipation or partnership headlines.
Over the past week, Wellgistics has issued multiple strategic updates. On May 13, a Kare PharmTech MSO pilot targeting the $14 billion RPM market saw shares rise 23.1%. A planned acquisition of WellCare Today on May 14 produced only a modest -3.09% move. The Q1 2026 financials and the multi-asset DelivMeds AI transaction on May 19–20 each coincided with -25.65% reactions. Today’s shareholder letter further elaborates on those transactions against this volatile backdrop.
Key Terms
blockchain technical
tokenization technical
smart contracts technical
glp-1 medical
biometric medical
pharmacodynamic monitoring medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare
PHILADELPHIA, PA / ACCESS Newswire / May 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company"), a provider of data monetization, credentialing, digital engagement, and real-world asset ('RWA') tokenization technologies, today entered into a fully binding term sheet (the "Binding Term Sheet") with Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today released a letter to shareholders expanding upon strategy behind recently announced transactions.
'Dear Fellow Shareholders,
Yesterday we announced a series of transactions that, taken together, mark the most consequential strategic moment in Wellgistics Health's history. We are writing today to explain what connects them - and why we believe the steps we are taking now will position Wellgistics as essential infrastructure for the healthcare industry of the next decade.
Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale. Every participant in healthcare - providers, payors, pharmacies, manufacturers, and patients - is operating with fragmented data, duplicated workflows, and trust gaps that cost the system hundreds of billions of dollars each year. We believe these inefficiencies cannot be solved by another point solution layered on top of legacy systems. They require a unified data fabric that captures, verifies, and exchanges health information across every node of care. That fabric will be built on blockchain. We believe it is not a question of whether the industry adopts blockchain-based infrastructure, but when - and who is positioned to provide it.
That conviction is the strategic logic behind every announcement we made yesterday.
DelivMeds AI and the expanded Datavault license give us the enabling intellectual property for commercial tokenized healthcare data management. Tokenization is the mechanism that turns fragmented health data into a verifiable, exchangeable, and valuable asset. By forming DelivMeds AI and consolidating these capabilities inside our EinsteinRx™ platform, we are building the data layer that the rest of the industry will eventually need to plug into.
The QOLPOM patent portfolio brings remote biometric patient verification, technology-enabled pharmacodynamic monitoring, and medical drone biometric IP under our roof. Verification is the foundation of trust in any tokenized data system. Without it, health data cannot be reliably exchanged or monetized. QOLPOM's IP gives us the authentication layer that makes the data layer credible. And it opens up a potential unique future last-mile solution using drones capable of biometric patient verification to deliver prescriptions and pickup diagnostic specimen collection for lab services in rural communities.
The Tollo Health controlling interest and Forzet™ extend our reach directly to the patient. Through the Health Lives Here program in partnership with NFL Alumni Health, we will engage GLP-1 patients managing muscle loss - generating real-world adherence, outcomes, and biometric data that flows back into our platform. This is vertical integration in practice: from the manufacturer relationship, through the pharmacy network, the prescription dispensing event, the patient's daily experience, and back into the data infrastructure that improves the next decision.
Each of these moves stands on its own. Together, they form a single integrated thesis. The pharmacy is the most under-appreciated touchpoint in healthcare - it is where prescriptions are filled, where adherence begins, and where the richest longitudinal data on patient behavior already lives. We have spent years building the connective tissue across 6,500 pharmacies and 200+ manufacturers. We are now extending that connective tissue upstream into data infrastructure and downstream into patient care.
The companies that will define healthcare over the next ten years will not be the ones with the best single product. They will be the ones who own the data, the verification, and the patient relationship - and who can move information across all three with cryptographic trust. That is what we are building.
We recognize that the breadth of yesterday's announcements raises questions, and we are committed to keeping our shareholders informed at every step. We will provide additional detail in the coming weeks as definitive agreements are finalized.
The planned share restructuring and new CUSIP support the Company's next phase of growth.
Thank you for your continued confidence in Wellgistics Health. We are building this Company with conviction, and we believe the foundation we are laying now will deliver durable value for shareholders, providers, and patients alike.'
Sincerely,
Gerald Commissiong
Interim Co-Chief Executive Officer
Prashant Patel
Interim Co-Chief Executive Officer
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August 2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding GLP-1 related opportunities, the integration of PharmacyChain™ functionality with EinsteinRx™, the potential expansion of the Datavault AI PharmacyChain™ license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant data transfer functionality, the potential acquisition of the QOLPOM IP portfolio, the potential acquisition of a controlling interest in Tollo Health, LLC, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "may," "will," "would," "could," "should," "seek," "estimate," "project," "potential," "continue" and similar expressions.
Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain™ functionality and other strategic initiatives; the Company's ability to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize and scale EinsteinRx™ and PharmacyChain™-enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare, FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings; the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire